PharmaEssentia Corporation

6446

TW0006446008

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
312.5 ^TWD	+0.64%		+1.13%	-9.68%

04-26	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI
04-24	PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	CI

PharmaEssentia Corporation cancelled the transaction announced on April 2, 2024

April 15, 2024

On April 16, 2024, PharmaEssentia Corporation cancelled the transaction.

Latest news about PharmaEssentia Corporation

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	04-26	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	04-24	CI
PharmaEssentia Corporation cancelled the transaction announced on April 2, 2024	04-15	CI
PharmaEssentia Corporation announced a financing transaction	04-01	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	03-28	CI
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	03-04	CI
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	03-04	CI
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
PharmaEssentia Corporation(TWSE:6446) added to Taiwan TAIEX Index	02-18	CI
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer	01-24	MT
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA	01-17	CI
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia	25/10/23	CI
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate	03/10/23	CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on July 28, 2023.	28/09/23	CI
PharmaEssentia Corporation's Equity Buyback announced on July 28, 2023, has closed with 4,000,000 shares, representing 1.19% for TWD 1,351.42 million	27/09/23	CI
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China	20/09/23	CI
PharmaEssentia Corporation(TPEX:6446) added to FTSE All-World Index	18/09/23	CI
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
PharmaEssentia Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 8,846.64 million.	28/07/23	CI
PharmaEssentia Corporation authorizes a Buyback Plan.	27/07/23	CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on May 24, 2023.	21/07/23	CI
PharmaEssentia Corporation's Equity Buyback announced on May 24, 2023, has expired with 4,001,000 shares, representing 1.31% for TWD 1,366.17 million.	20/07/23	CI
Certain Common Shares of PharmaEssentia Corporation are subject to a Lock-Up Agreement Ending on 18-JUL-2023.	17/07/23	CI
PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as BesremiÂ®) for the Treatment of Patients with Polycythemia Vera (PV)	30/06/23	CI

Chart PharmaEssentia Corporation

Duration

Period

More charts

PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

12/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for PharmaEssentia Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

312.5 TWD

Average target price

417.2 TWD

Spread / Average Target

+33.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMAESSENTIA CORPORATION	-9.68%	3.2B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs